PMGC Holdings (ELAB) Profit After Tax (2022 - 2026)
PMGC Holdings (ELAB) posted Profit After Tax of -$5.0 million for Q1 2026, down 67.19% sequentially from -$3.0 million in Q4 2025, and down 4577.37% YoY from $111377.0 in Q1 2025.
PMGC Holdings (ELAB) Profit After Tax (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Profit After Tax for 5 years, with the latest figure at -$5.0 million in Q1 2026.
- Quarterly Profit After Tax fell 4577.37% year-over-year to -$5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.6 million (down 321.0% YoY) and the FY2025 annual result came in at -$7.7 million, down 92.89% from the prior year.
- Profit After Tax declined to -$5.0 million in Q1 2026 per ELAB's latest filing, from -$3.0 million in the prior quarter.
- Over five years, Profit After Tax peaked at $1.1 billion in Q4 2022 and troughed at -$499.3 million in Q3 2022.
- A 5-year average of $41.8 million and a median of -$1.3 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2026: Profit After Tax soared 125.4% in 2024, then sank 4577.37% in 2026.
- Over 5 years, Profit After Tax stood at $1.1 billion in 2022, then sank by 100.1% to -$1.2 million in 2023, then jumped by 125.4% to $294284.0 in 2024, then tumbled by 1113.54% to -$3.0 million in 2025, then tumbled by 67.19% to -$5.0 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$5.0 million, -$3.0 million, and -$2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | -2.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.99 Mn |
| Dec 31, 2025 | -2.98 Mn |
| Sep 30, 2025 | -2.59 Mn |
| Jun 30, 2025 | -2.00 |
| Mar 31, 2025 | 111,377.00 |
| Dec 31, 2024 | 294,284.00 |
| Sep 30, 2024 | -1.50 Mn |
| Jun 30, 2024 | -1.41 Mn |
| Mar 31, 2024 | -1.40 Mn |
| Dec 31, 2023 | -1.16 Mn |
| Sep 30, 2023 | -782,660.00 |
| Jun 30, 2023 | -1.28 Mn |
| Mar 31, 2023 | -1.08 Mn |
| Dec 31, 2022 | 1.15 Bn |
| Sep 30, 2022 | -499.31 Mn |